Papers

1

Total Citations

2

H-Index

1

About

Dr. Shengjun Luo is a dedicated clinician-researcher specializing in hereditary renal cancer syndromes, with a particular focus on the management of HLRCC-associated renal cell carcinoma (RCC). Her work addresses the critical intersection of genetic predisposition, surgical oncology, and reproductive health. In her notable 2022 case report, Dr. Luo documented the first known instance of a patient with bilateral HLRCC-associated RCC successfully undergoing two partial nephrectomies and subsequently achieving a safe pregnancy. This contribution, cited 2 times, provides essential guidance for managing fertility and pregnancy in young patients with this rare autosomal dominant condition caused by FH gene mutations. By demonstrating that aggressive nephron-sparing surgery can preserve renal function and allow for safe childbearing, her work directly impacts clinical decision-making for a vulnerable population. Dr. Luo’s research underscores the importance of multidisciplinary care in hereditary cancer syndromes, offering hope and practical pathways for patients navigating both cancer treatment and family planning.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
Case report: Going through pregnancy safely after twice partial nephrectomy for bilateral kidneys with HLRCC-associated RCC
2 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: First Affiliated Hospital of Chongqing Medical University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 10 days ago